127 related articles for article (PubMed ID: 3839284)
41. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
Jehn U; Heinemann V; Wilmanns W
Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
[TBL] [Abstract][Full Text] [Related]
42. Acridinyl anisidide (m-AMSA) therapy in 11 patients with refractory acute leukemia.
Naparstek E; Shinar E; Polliack A
Isr J Med Sci; 1984 Feb; 20(2):118-22. PubMed ID: 6546740
[TBL] [Abstract][Full Text] [Related]
43. Acute electrocardiographic changes induced by amsacrine.
Shinar E; Hasin Y
Cancer Treat Rep; 1984 Sep; 68(9):1169-72. PubMed ID: 6592038
[TBL] [Abstract][Full Text] [Related]
44. Results of induction and consolidation treatment with intermediate and high-dose ara-C and m-AMSA containing regimens in patients with primarily failed or relapsed acute leukemia and non-Hodgkin's lymphoma.
Peters WG; Willemze R; Colly LP
Scand J Haematol Suppl; 1986; 44():7-16. PubMed ID: 3515513
[No Abstract] [Full Text] [Related]
45. m-AMSA: a review of clinical data.
Zittoun R
Eur J Cancer Clin Oncol; 1985 Jun; 21(6):649-53. PubMed ID: 3894030
[No Abstract] [Full Text] [Related]
46. Mitoxantrone and VP-16 in refractory acute myelogenous leukemia.
Ho AD; Lipp T; Ehninger G; Meyer P; Rückle H; Steinke B; Kaboth W; Körbling M
Onkologie; 1986 Jun; 9(3):148-50. PubMed ID: 3528961
[TBL] [Abstract][Full Text] [Related]
47. Chemotherapy for relapsed and resistant acute nonlymphoblastic leukemia. Effect of ATA, an amsacrine-containing regime.
Liang R; Chan TK; Todd D
Cancer Chemother Pharmacol; 1988; 21(1):68-70. PubMed ID: 3342467
[TBL] [Abstract][Full Text] [Related]
48. [Phase II study of AMSA in adults with acute therapy-refractory leukemias].
Fiebig HH; Henss H; Engelhardt R; Hoelzer D; Pralle H; Link H; Schmitz R
Onkologie; 1983 Aug; 6(4):188-90. PubMed ID: 6355948
[TBL] [Abstract][Full Text] [Related]
49. Amsacrine (AMSA)--a clinical review.
Louie AC; Issell BF
J Clin Oncol; 1985 Apr; 3(4):562-92. PubMed ID: 3884748
[No Abstract] [Full Text] [Related]
50. Phase I and II study of AMSA in childhood tumours.
Goldman A; Malpas JS
Cancer Chemother Pharmacol; 1982; 9(1):53-6. PubMed ID: 6958393
[TBL] [Abstract][Full Text] [Related]
51. Continuous infusion diaziquone and etoposide: a phase I study in adult patients with acute leukemia.
Lee EJ; Reck K; Schiffer CA
Leukemia; 1990 Mar; 4(3):189-92. PubMed ID: 2314118
[TBL] [Abstract][Full Text] [Related]
52. Pilot studies of various combinations of dibromodulcitol, VP-16, and AMSA.
Eagan RT
Oncology; 1982; 39(5):295-7. PubMed ID: 6896559
[TBL] [Abstract][Full Text] [Related]
53. Phase II trial of amsacrine (m-AMSA) in advanced ovarian carcinoma.
Dombernowsky P; Siegenthaler P; Somers R; Hansen HH
Eur J Cancer Clin Oncol; 1982 Jan; 18(1):71-4. PubMed ID: 6896306
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of AMSA in children with acute leukemia. A Pediatric Oncology Group study.
Krischer J; Land VJ; Civin CI; Ragab AH; Mahoney DH; Frankel LS
Cancer; 1984 Jul; 54(2):207-10. PubMed ID: 6586277
[TBL] [Abstract][Full Text] [Related]
55. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
Woodcock TM; Schneider RJ; Young CW
Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
[TBL] [Abstract][Full Text] [Related]
56. Amsacrine in refractory adult acute leukemia: a pilot study of the Southeastern Cancer Study Group.
Winton EF; Hearn EB; Vogler WR; Johnson L; Logan T; Raney M
Cancer Treat Rep; 1983 Nov; 67(11):977-80. PubMed ID: 6580070
[TBL] [Abstract][Full Text] [Related]
57. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
Hijiya N; Gaynon P; Barry E; Silverman L; Thomson B; Chu R; Cooper T; Kadota R; Rytting M; Steinherz P; Shen V; Jeha S; Abichandani R; Carroll WL
Leukemia; 2009 Dec; 23(12):2259-64. PubMed ID: 19741725
[TBL] [Abstract][Full Text] [Related]
58. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
59. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
Weil M; Auclerc MF; Schaison G; Auclerc G; Daubrisson A; Degos L; Caro J; Marty M; Jacquillat GI
Nouv Presse Med; 1982 Oct; 11(39):2911-4. PubMed ID: 6755389
[TBL] [Abstract][Full Text] [Related]
60. [4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) combination salvage therapy in refractory acute non-lymphocytic leukemia in adults].
Mukaiyama T; Ogawa M; Horikoshi N; Inoue K; Fukutani H; Tabata M; Hirano A; Mizunuma N; Itami S
Gan To Kagaku Ryoho; 1989 May; 16(5):2019-23. PubMed ID: 2730091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
